{"id":59567,"date":"2026-03-16T13:59:35","date_gmt":"2026-03-16T05:59:35","guid":{"rendered":"https:\/\/flcube.com\/?p=59567"},"modified":"2026-03-16T13:59:36","modified_gmt":"2026-03-16T05:59:36","slug":"yoltechs-yolt-202-wins-fda-phase-ii-iii-approval-in-vivo-base-editing-gene-therapy-targets-alpha-1-antitrypsin-deficiency","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59567","title":{"rendered":"YolTech&#8217;s YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency"},"content":{"rendered":"\n<p><strong>YolTech Therapeutics<\/strong> announced <strong>FDA clearance<\/strong> to initiate an <strong>open-label, single-dose expansion Phase II\/III clinical study<\/strong> for <strong>YOLT-202<\/strong>, its <strong>in vivo gene editing drug<\/strong> for <strong>alpha-1 antitrypsin deficiency (AATD)<\/strong>. The <strong>first-in-class therapeutic<\/strong>, based on YolTech&#8217;s proprietary <strong>YolBE next-generation adenine base editor<\/strong>, enables <strong>precise correction of the SERPINA1 PiZ mutation to normal PiM<\/strong> in hepatocytes, restoring <strong>functional AAT protein expression<\/strong> while <strong>avoiding bystander editing<\/strong>. With <strong>prior FDA Orphan Drug Designation<\/strong>, YOLT-202 represents a <strong>potential &#8220;one-shot cure&#8221;<\/strong> for the <strong>genetic disorder<\/strong> affecting <strong>95% of severely affected PiZZ genotype patients<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase II\/III clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>YOLT-202<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>In vivo gene editing therapy (adenine base editor)<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>YolBE \u2013 next-generation adenine base editor (self-developed)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>SERPINA1 PiZ locus (Glu342Lys mutation)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Converts PiZ mutation to normal PiM; restores functional AAT protein in hepatocytes<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Alpha-1 antitrypsin deficiency (AATD)<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Open-label, single-dose expansion Phase II\/III<\/td><\/tr><tr><td><strong>Prior Designation<\/strong><\/td><td>FDA Orphan Drug Designation (ODD)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>YolTech Therapeutics (China-based)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gene-editing-technology-amp-differentiation\">Gene Editing Technology &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>YOLT-202 \/ YolBE Platform Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Editor Class<\/strong><\/td><td>Adenine base editor (ABE) \u2013 next-generation<\/td><\/tr><tr><td><strong>Precision<\/strong><\/td><td>Single-base conversion (A\u2192G) at PiZ locus<\/td><\/tr><tr><td><strong>Target Locus<\/strong><\/td><td>SERPINA1 PiZ (Glu342Lys) \u2192 PiM (normal)<\/td><\/tr><tr><td><strong>Bystander Editing<\/strong><\/td><td><strong>Almost completely avoided<\/strong> \u2013 key safety advantage<\/td><\/tr><tr><td><strong>Delivery<\/strong><\/td><td>In vivo (liver-directed)<\/td><\/tr><tr><td><strong>Therapeutic Goal<\/strong><\/td><td>Permanent correction; &#8220;one-shot cure&#8221; potential<\/td><\/tr><tr><td><strong>Cell Type<\/strong><\/td><td>Hepatocytes (AAT production site)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AATD Genetics:<\/strong> SERPINA1 mutations \u2192 misfolded AAT protein \u2192 polymerization \u2192 lung (COPD) and liver damage<\/li>\n\n\n\n<li><strong>PiZ Allele:<\/strong> Most common severe mutation (Glu342Lys); >95% of severe patients are PiZZ homozygous<\/li>\n\n\n\n<li><strong>Base Editing Advantage:<\/strong> Direct DNA correction without double-strand breaks (vs. CRISPR-Cas9); reduced off-target risk<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-context-amp-unmet-need\">Disease Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Alpha-1 Antitrypsin Deficiency (AATD)<\/th><\/tr><\/thead><tbody><tr><td><strong>Genetics<\/strong><\/td><td>SERPINA1 gene mutations; Z and S alleles most common<\/td><\/tr><tr><td><strong>Pathophysiology<\/strong><\/td><td>Misfolded AAT protein polymerizes; trapped in hepatocytes; low circulating AAT \u2192 lung elastase damage<\/td><\/tr><tr><td><strong>Clinical Manifestations<\/strong><\/td><td>Chronic obstructive pulmonary disease (COPD); liver cirrhosis; hepatocellular carcinoma<\/td><\/tr><tr><td><strong>PiZZ Genotype<\/strong><\/td><td>&gt;95% of severely affected patients; focus of YOLT-202 development<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Weekly IV AAT augmentation (Prolastin); lung\/liver transplant for end-stage disease<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>No curative therapy; augmentation expensive and inconvenient; progressive organ damage despite treatment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-competitive-landscape\">Strategic Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Gene Editing Race<\/strong><\/td><td>Intellia (NTLA-2002, NTLA-3001), Beam Therapeutics (BEAM-302) also developing AATD base editors; YolTech China-based but U.S.-first development strategy<\/td><\/tr><tr><td><strong>In Vivo Advantage<\/strong><\/td><td>Direct liver delivery vs. ex vivo cell editing; eliminates cell therapy manufacturing complexity<\/td><\/tr><tr><td><strong>Bystander Avoidance<\/strong><\/td><td>YolBE precision differentiates from earlier base editors; safety profile critical for regulatory approval<\/td><\/tr><tr><td><strong>&#8220;One-Shot Cure&#8221;<\/strong><\/td><td>Functional cure potential commands premium pricing; addresses lifetime augmentation cost (~$100K\/year)<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>China NMPA filing anticipated; EU EMA orphan designation likely<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Approach<\/th><th>Status<\/th><th>YOLT-202 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Intellia<\/strong><\/td><td>NTLA-2002<\/td><td>CRISPR in vivo (knockout SERPINA1 Z allele)<\/td><td>Phase I<\/td><td>Base editing (correction) vs. knockout; preserves normal allele function<\/td><\/tr><tr><td><strong>Beam Therapeutics<\/strong><\/td><td>BEAM-302<\/td><td>Base editing (similar PiZ\u2192PiM)<\/td><td>Preclinical\/Phase I<\/td><td>YolTech first to Phase II\/III; China-based cost advantage<\/td><\/tr><tr><td><strong>Vertex\/Arrowhead<\/strong><\/td><td>VX-864 (RNAi)<\/td><td>Small molecule corrector (discontinued)<\/td><td>Discontinued<\/td><td>Gene editing permanent vs. pharmacological chaperone<\/td><\/tr><tr><td><strong>YolTech<\/strong><\/td><td><strong>YOLT-202<\/strong><\/td><td><strong>YolBE base editing (PiZ\u2192PiM)<\/strong><\/td><td><strong>Phase II\/III-ready<\/strong><\/td><td><strong>First to late-stage; almost no bystander editing; in vivo delivery<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase II\/III<\/strong><\/td><td>2026-2028<\/td><td>Efficacy (serum AAT levels, liver function); safety; durability of correction<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>2028<\/td><td>Normalization of AAT levels; reduction in liver polymers; pulmonary function preservation<\/td><\/tr><tr><td><strong>Regulatory Filing<\/strong><\/td><td>2028-2029<\/td><td>U.S. BLA (Breakthrough Therapy designation potential); EU MAA; China NDA<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2029-2030<\/td><td>Specialty pharmacy distribution; patient identification (PiZZ genotype screening)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II\/III outcomes, base editing durability, and competitive positioning for YOLT-202. Actual results may differ due to in vivo editing efficiency challenges, immune responses to delivery vectors, and competitive dynamics with other gene editing approaches.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\/III clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,66,1168],"class_list":["post-59567","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-gene-therapy","tag-yoltech-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>YolTech&#039;s YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech&#039;s proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential &quot;one-shot cure&quot; for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59567\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YolTech&#039;s YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency\" \/>\n<meta property=\"og:description\" content=\"YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech&#039;s proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential &quot;one-shot cure&quot; for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59567\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T05:59:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-16T05:59:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59567#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59567\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"YolTech&#8217;s YOLT-202 Wins FDA Phase II\\\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency\",\"datePublished\":\"2026-03-16T05:59:35+00:00\",\"dateModified\":\"2026-03-16T05:59:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59567\"},\"wordCount\":653,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Gene therapy\",\"YolTech Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59567#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59567\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59567\",\"name\":\"YolTech's YOLT-202 Wins FDA Phase II\\\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-16T05:59:35+00:00\",\"dateModified\":\"2026-03-16T05:59:36+00:00\",\"description\":\"YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\\\/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech's proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential \\\"one-shot cure\\\" for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59567#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59567\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59567#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YolTech&#8217;s YOLT-202 Wins FDA Phase II\\\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"YolTech's YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency - Insight, China&#039;s Pharmaceutical Industry","description":"YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech's proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential \"one-shot cure\" for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59567","og_locale":"en_US","og_type":"article","og_title":"YolTech's YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency","og_description":"YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech's proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential \"one-shot cure\" for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.","og_url":"https:\/\/flcube.com\/?p=59567","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T05:59:35+00:00","article_modified_time":"2026-03-16T05:59:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59567#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59567"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"YolTech&#8217;s YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency","datePublished":"2026-03-16T05:59:35+00:00","dateModified":"2026-03-16T05:59:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59567"},"wordCount":653,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Gene therapy","YolTech Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59567#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59567","url":"https:\/\/flcube.com\/?p=59567","name":"YolTech's YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-16T05:59:35+00:00","dateModified":"2026-03-16T05:59:36+00:00","description":"YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II\/III clinical study for YOLT-202, its in vivo gene editing drug for alpha-1 antitrypsin deficiency (AATD). The first-in-class therapeutic, based on YolTech's proprietary YolBE next-generation adenine base editor, enables precise correction of the SERPINA1 PiZ mutation to normal PiM in hepatocytes, restoring functional AAT protein expression while avoiding bystander editing. With prior FDA Orphan Drug Designation, YOLT-202 represents a potential \"one-shot cure\" for the genetic disorder affecting 95% of severely affected PiZZ genotype patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59567#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59567"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59567#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"YolTech&#8217;s YOLT-202 Wins FDA Phase II\/III Approval \u2013 In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59567"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59567\/revisions"}],"predecessor-version":[{"id":59569,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59567\/revisions\/59569"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}